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Abstract
Background: Gene expression profiling may improve prognostic accuracy in patients with early breast cancer. Our 
objective was to demonstrate that it is possible to develop a simple molecular signature to predict distant relapse.
Methods: We included 153 patients with stage I-II hormonal receptor-positive breast cancer. RNA was isolated from 
formalin-fixed paraffin-embedded samples and qRT-PCR amplification of 83 genes was performed with gene 
expression assays. The genes we analyzed were those included in the 70-Gene Signature, the Recurrence Score and the 
Two-Gene Index. The association among gene expression, clinical variables and distant metastasis-free survival was 
analyzed using Cox regression models.
Results: An 8-gene prognostic score was defined. Distant metastasis-free survival at 5 years was 97% for patients 
defined as low-risk by the prognostic score versus 60% for patients defined as high-risk. The 8-gene score remained a 
significant factor in multivariate analysis and its performance was similar to that of two validated gene profiles: the 70-
Gene Signature and the Recurrence Score. The validity of the signature was verified in independent cohorts obtained 
from the GEO database.
Conclusions: This study identifies a simple gene expression score that complements histopathological prognostic 
factors in breast cancer, and can be determined in paraffin-embedded samples.
Background
A key aspect of the management of women with early
breast cancer is the selection of adjuvant therapy, which is
guided by the use of prognostic factors included in the
guidelines[1,2]. However, the use of these criteria leads to
unnecessary treatment in many women. Gene expression
profiles may improve prognostic and predictive informa-
tion in breast cancer patients, so that adjuvant chemo-
therapy is given only to those with the higher risk. A
number of such profiles are currently available and two of
them, the 70-Gene Signature (MammaPrint™) and the
Recurrence Score (OncoType™) are being evaluated in
phase III studies [3,4].
The major drawbacks to the widespread use of gene
expression profiling include reservations regarding their
cost/effectiveness ratio and their lack of widespread avail-
ability. For some profiles, the need for fresh-frozen bio-
logical samples adds to these drawbacks. We have
previously demonstrated that 1) quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR) can
be used to assess the genes included in the 70-Gene Sig-
nature and 2) commercially available probes can be used
on formalin-fixed, paraffin-embedded (FFPE) samples to
determine the 70-Gene Signature, the Recurrence Score
and the Two-Gene Ratio [5,6].
In the present study, we sought to identify a gene
expression profile based on the genes included in the 70-
Gene Signature, the Recurrence Score and the Two-Gene
Ratio. Our hypotheses were as follows: 1) commercially
available assays can be used to quantify gene expression
by qRT-PCR using RNA extracted from FFPE tissues and
* Correspondence: jafresno@gmail.com, eespinosa00@terra.es
1 Unidad de Investigación, Instituto de Investigación Sanitaria IdIPAZ, Hospital 
Universitario La Paz (Paseo de la Castellana, 261), Madrid (28046), Spain
2 Service of Oncology, IdIPAZ, Hospital Universitario La Paz (Paseo de la 
Castellana, 261), Madrid (28046), Spain
† Contributed equally
Full list of author information is available at the end of the articleSánchez-Navarro et al. BMC Cancer 2010, 10:336
http://www.biomedcentral.com/1471-2407/10/336
Page 2 of 10
2) it is possible to find a prognostic gene expression pro-
file using a reduced number of genes.
Methods
Patients and clinical data
Case selection was performed retrospectively. To be
included in the study, patients had to have stage I or II
(TNM classification, 2002) estrogen and/or progesterone
receptor-positive invasive ductal breast cancer. Patients
also had to have tissue samples available for gene expres-
sion analysis, and were required to have received appro-
priate therapy (according to standard protocols) during
the inclusion period. Appropriate therapy was defined as
either mastectomy or tumorectomy plus adjuvant radio-
therapy, as well as adjuvant hormonal therapy for 5 years
in all patients and adjuvant anthracycline-based chemo-
therapy in N+ or in N0 patients with poor prognostic fea-
tures. A minimum follow-up of 5 years was also required
for all patients who did not relapse. Institutional approval
from our ethics committee was obtained before the study
was initiated.
RNA isolation and cDNA synthesis
The biological specimens used in this study were FFPE
samples stored at the Pathology Department of our insti-
tution. An experienced pathologist evaluated H&E prepa-
rations to select samples containing at least 70% tumor
cells. Fifteen 5-μm sections from each FFPE sample were
de-paraffinized with xylene and washed with ethanol.
RNA was then extracted with the Master Pure™ Kit (Epi-
centre). We normalized to total RNA input; therefore,
first-strand cDNA was synthesized from 1 μg of total
RNA using random primers, according to the High
Capacity cDNA Reverse Transcription Kit protocol
(Applied Biosystems).
Quantitative RT-PCR
qRT-PCR amplifications were performed with TaqMan
Gene Expression Assay products in an ABI PRISM 7900
HT Sequence Detection System (Applied Biosystems).
The reactions were carried out using TaqMan Low Den-
sity Arrays (TLDAs, Applied Biosystems). TLDAs have
proved appropriate for assessment of FFPE samples [7].
For quality control, samples with insufficient tumor tis-
sue, insufficient RNA (less than 1 μg), or a weak RT-PCR
signal (average cycle threshold for the reference genes
greater than 35) were excluded. A preliminary analysis
was performed to compare gene expression measure-
ments between paired FF and FFPE samples. The mean
coefficient of variation for the same assays performed on
different days or in different batches was less than 3%.
Gene selection
We configured a TLDA series to analyze the genes
included in the 70-Gene Signature[8], the Recurrence
Score [3] and the Two-Gene Ratio[9] with available Taq-
Man Gene Expression Assays (Supplementary table 1).
Calculation of gene expression
Average cycling threshold (Ct) values[10], were obtained
using SDS 2.2 software (Applied Biosystems). The maxi-
mum Ct value was set at 40. Ct values were normalized
using four housekeeping genes (IPO8, HMBS, POLR2A
and SDHA). The relative expression level of each target
gene was expressed as ΔCt = Ctref - Ctgene[11]. Reference-
normalized expression measurements were adjusted by
defining the lowest expression value as 0, with subse-
Table 1: Clinical characteristics of the included patients*
Median age: 58 years, range 29-82
Number of patients (%)
T
1 77 (50.3%)
2 76 (49.7%)
N
0 96 (62.7%)
1 57 (37.3%)
Stage
I 61 (39.9%)
IIa 51 (33.3%)
IIb 41 (26.8%)
Hormone receptor status
ER+/PgR- 30 (19.6%)
ER+/PgR+ 110 (71.9%)
ER+/PgR unknown 12 (7.9%)
ER-/PgR+ 1 (0.7%)
Grade
1 29 (18.9%)
2 64 (41.8%)
3 59 (38.6%)
Unknown 1 (0.7%)
Chemotherapy
No chemotherapy 56 (36.6%)
CMF 42 (27.4%)
Anthracycline-based 55 (35.9%)
* All patients received adjuvant tamoxifen.
CMF: cyclophosphamide, methotrexate, 5-fluorouracilSánchez-Navarro et al. BMC Cancer 2010, 10:336
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quent 1-unit increases reflecting an approximate dou-
bling of the RNA [3].
Methodology used to find a reduced profile
First, genes displaying poor correlation in gene expres-
sion levels between fresh frozen and FFPE samples were
discarded, as described elsewhere [12]. We computed a
statistical significance level for each gene based on a uni-
variate proportional hazards model [13] with the aim of
identifying genes whose expression was significantly
related to the distant metastasis-free survival (DMFS).
Genes related to DMFS were subsequently filtered based
on their p-values (p < 0.005) and the correlation between
them. We then selected genes with the lowest p-values in
each correlation group [3]). These selected genes were
used to develop a gene expression-based prediction
model of recurrence risk using the supervised principal
component method of E. Bair and R. Tibshirani [14].
Leave-one-out cross-validation was used to evaluate the
predictive accuracy of the profile. It was also used for ini-
tial screening of the genes. The cutoff point was estab-
lished prior to gene selection including all samples. We
assessed cutoff points leaving from 10% to 90% of
patients in the low risk group and increasing by 10% each
time. To test the statistical significance of each cutoff
point, the p-value of the log-rank test statistic for the risk
groups was evaluated using 1000 random permutations.
Analyses were performed in BRB-ArrayTools v3.6.1
developed by R. Simon and A. Peng. We used the
REMARK guidelines to ensure that the manuscript pro-
vided relevant information [15]. Additional description of
the methods can be found in supplemental PDF file
(Additional file 1, Additional methods).
Statistical analyses
To evaluate the prognostic value of the reduced gene
score in our patient population, survival curves were esti-
mated using Kaplan-Meier analysis and compared using
the log-rank test. Univariate and multivariate Cox pro-
portional-hazards analyses were also employed to create
a final model that included the tumor grade (1 vs. 2 and 1
vs. 3), size (≤2 cm vs. >2 cm) and nodal status (0 vs. 1-3
positive nodes). Like other studies examining gene pro-
files in breast cancer, DMFS was the primary end point.
Two-way contingency-table analyses, as well as calcula-
tions of Cramer's V statistic, were also performed to mea-
sure the strength of the association between the 8-Gene
Score (the score we identified) and the 70-Gene Signature
and the Recurrence Score[16]. To assess model accuracy
at five years, Harrell's bias-corrected concordance index
was calculated. Models were refit 500 times using the
bootstrap resampling technique. The concordance index
is the percentage of patient pairs in which the predicted
and observed outcomes coincide, such that c = 0.5 repre-
sents agreement by chance and c = 1.0 represents perfect
discrimination[17]. Concordance is identical to the area
under a receiver operating characteristic curve
(ROC)[18].
To define the continuous relationship between the 8-
gene Score and the 5-year DMFS rate, Gray's piecewise-
constant time-varying coefficients model was used[19]. A
linear tail-restricted cubic spline function was generated
using "R" v 2.4.1 with the Design software package v2.0-
12.
Independent data sets
Four independent databases that are available online were
used as validation sets: 1) NKI [8], downloaded from the
Rosetta Inpharmatics Web page http://www.rii.com/pub-
lications/2002/nejm.html, 2) SWE (GSE1456)[20], 3) UPP
(GSE4922)[21], and 4) LOI (GSE6532) [22], downloaded
from the NCBI GEO data repository http://
www.ncbi.nlm.nih.gov/projects/geo/index.cgi. To apply
our qRT-PCR reduced gene score to these microarray
data sets, the expression values of each set were z-score
transformed [23]. Expression values were adjusted, with
the lowest expression value defined as 0 and other values
scaled accordingly. Per-gene normalization within the
validation cohorts was performed using median values
obtained in the discovery cohort [24]. Survival curves
were then estimated.
SPSS v9.1 software package and "R" v 2.4.1 (with the
Design software package v2.0-12) were used for all statis-
tical analyses. All P values were two-sided, and P < 0.05
was considered statistically significant.
Results
We considered 736 patients for inclusion in the study and
a total of 153 patients were finally included. Additional
f i l e  2  T a b l e  S 1  i n c l u d e s  r a w  d a t a  o f  g e n e  e x p r e s s i o n ,
whereas Additional file 3 Table S2 checks the REMARK
recommendations along the manuscript. Table 1
describes the clinical features of and therapies received by
the 153 patients. The median age was 58 years and the
median follow-up was 91 months. Thirty-four patients
(22%) had a distant relapse, of whom 17 died and 7 were
lost to follow-up after the relapse. Among 119 patients
who did not have a distant relapse, four had a local/
regional recurrence that was successfully treated with
surgery.
We first selected 53 genes that exhibited highly corre-
lated expression levels in FF and FFPE samples. Seven-
teen genes were subsequently filtered based on their P-
values related to DMFS. A model was built using these 17
genes (data not shown). Models with 10, 8, 7 or even
fewer genes also demonstrated a good separation
between groups at a low and high risk of distant recur-
rence. We selected a score based on 8 genes because itSánchez-Navarro et al. BMC Cancer 2010, 10:336
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demonstrated the best performance. The 8-gene Score
was calculated for each sample using reference-normal-
ized expression measurements based on the following
equation:
8-gene Score = 0.1936*DTL + 0.2176*ECT2 +
0.0454*MTDH + 0.1329*PRC1 + 0.0556*RFC4 -
0.1913*SCUBE2 - 0.0443*STK32B - 0.1182*ZNF533.
Table 2 displays the names and coefficients of these 8
genes. Increased expression levels of DTL, ECT2,
M T D H ,  P R C 1  a n d  R F C 4  w e r e  as s oc ia t ed  wi t h  s h o rt e r
disease-free survival, whereas increased expression levels
of SCUBE2, STK32B, and ZNF533 were associated with
longer disease-free survival. All of these genes are
included in the 70-Gene Signature, although SCUBE2 is
also included in the Recurrence Score.
BRB ArrayT ools was used to define a cutoff point for
risk stratification. We assessed cut-off points leaving
from 10% to 90% of patients in the low risk group increas-
ing by 10% each time. Best performance was obtained
when 60% of the patients were allocated to the low-risk
group. Patients with a total score <2.86 were assigned to
the low risk of recurrence group and patients with a score
≥2.86 constituted the high risk of recurrence group. The
P-value of the log-rank test used to calculate recurrence
risk between risk groups based on 1000 permutations was
0.018.
DMFS at five years was 97.7% for patients in the low-
risk group and 60.6% for patients in the high-risk group
(HR: 20.4, CI 95%: 6.2 - 67.5; p < 0.001) (Figure 1A).
DMFS at five years decreased continuously as the 8-Gene
Score increased (Figure 2). Overall survival at five years
was also calculated, and was found to be 98.9% for the
low-risk group and 86.6% for the high-risk group (HR:
7.496, CI 95%: 2.4 - 23.4; p < 0.001). A univariate analysis
evaluating the effects of pathological factors on DMFS
and OS is presented in Additional file 4 Table S3.
A sub-analysis was performed to evaluate the influence
of lymph node status on DMFS (Figures 1B and 1C). In
patients with lymph node involvement, the 8-gene Score
included half of each group (low- vs. high-risk), and
DMFS at five years was 93.3% vs. 39.5%, respectively. In
women without lymph node involvement, the five-year
DMFS rates were 100% vs. 75.7%, respectively. We also
evaluated the performance in the population of patients
receiving just endocrine therapy and no chemotherapy
(figure 1D).
The multivariate Cox proportional hazards analysis
included the 8-gene Score, tumor size, nodal status and
tumor grade. The 8-gene Score was able to predict DMFS
(Table 3), indicating that this gene expression profile
added important prognostic information beyond that
provided by clinical factors. Lymph node status remained
the only clinical factor with significant independent pre-
dictive value.
We used Cramer's V statistic to asses the concordance
between other gene profiles [3,4] and the 8-gene Score.
The correlation between the 8-gene Score and the 70-
Gene Signature was 0.65 and the correlation was 0.58 for
the Recurrence Score and 0.30 for the Two-Gene Index.
These results indicate that there is a strong correlation
between the 8-gene Score and both the 70-Gene Signa-
ture and the Recurrence Score. To assess the discrimina-
t i v e  c a p a b i l i t y  o f  e a c h  p r o g n o s t i c  p r o f i l e  a t  f i v e  y e a r s ,
Harrell's bias-corrected concordance index was calcu-
lated. The calculated values were as follows: 8-gene Score
Table 2: Identification of the genes included in the 8-Gene Score
Gene p-value Score coefficient RefSeq Assay ID
DTL 1.2e-06 0.1936 NM_016448.2 Hs00212788_m1
ECT2 2.8e-06 0.2176 NM_018098.4 Hs00216455_m1
MTDH 2.9e-06 0.0454 NM_178812.2 Hs00757841_m1
PRC1 <1e-07 0.1329 NM_003981.2 Hs00187740_m1
RFC4 0.0002592 0.0556 NM_181573.2 Hs00427469_m1
SCUBE2 0.0005634 -0.1913 NM_020974.1 Hs00221277_m1
STK32B 0.0004406 -0.0443 NM_018401.1 Hs00179683_m1
ZNF533 2.13e-05 -0.1182 NM_152520.4 Hs00332216_m1Sánchez-Navarro et al. BMC Cancer 2010, 10:336
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= 0.81, Recurrence Score = 0.73, 70-Gene Signature =
0.70, and Two-Gene Index = 0.59.
We then applied the 8-gene Score to an online database
from the Dutch Cancer Institute (NKI) that has been pre-
viously used to compare several gene profiles[16]. The 8-
gene Score identified significant differences in DMFS for
the entire group of 295 patients (Figure 3), as well as for
the N+, N-, and ER + subgroups based on their score
(Additional file 5 table S4). In comparison with the 70-
Gene Signature, the 8-gene Score categorized more
Figure 1 Kaplan-Meier curves showing distant metastasis-free survival (DMFS) for low-risk and high-risk patient groups (as defined by the 
8-gene Score). A: all 153 patients included in this study B: patients with positive lymph nodes C: patients with negative lymph nodes D: patients who 
did not receive chemotherapySánchez-Navarro et al. BMC Cancer 2010, 10:336
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patients as being low-risk, and DMFS was a bit lower for
all groups. However, if the cutoff value was modified to
include the same number of patients in the low-risk cate-
gory as in the 70-Gene Signature, then the results for
DMFS were virtually identical.
We subsequently analyzed the performance of the 8-
gene Score in three additional data sets: SWE
(GSE1456)[20], UPP (GSE4922)[21], and LOI
(GSE6532)[22]. Although the use of other external data-
bases does not constitute a formal validation, it may pro-
vide insight about the performance of the gene set. A
similar approach has recently been reported in bladder
carcinoma [25]. In all data sets, the 8-Gene Score was
able to identify significant differences in DMFS (figure 3).
In all cases, the 8-gene Score assigned more than 55% of
the patients to the low-risk group. It predicted a DMFS
rate of >90% in the LOI and SWE data sets, and >80% in
the UPP data set.
Discussion
In the present study, we propose a qRT-PCR-derived
prognostic score based on the expression levels of eight
genes (the 8-Gene Score) for use in women with early
breast cancer. The score can be determined using FFPE
samples. It identified patients at high risk of recurrence in
our series of patients as well as in four independent data-
bases available online.
In comparison with women included in the other
online databases, all of our patients received tamoxifen
and two thirds were also treated with chemotherapy. The
fact that the 8-gene Score worked well in these databases
reflects its strength as a prognostic tool that can be used
in large populations. Our gene expression profile was
developed using hormonal receptor-positive tumors and,
although it was derived from a signature validated in both
positive and negative tumors [4], it should not be used for
women with hormone receptor-negative tumors.
The genes included in the 8-gene Score are also part of
the 70-Gene Signature, but the former should not be con-
sidered a scaled down version of the latter, because the 8-
G e n e  S c o r e  i s  a p p l i c a b l e  t o  F F P E  s a m p l e s  a n d  c a n  b e
obtained using commercially available probes. Models
with fewer than 8 genes performed similarly to the 8-gene
Score, but the 8-gene Score was finally selected because it
was more stable than smaller models and, at the same
time, did not contain redundant information.
DTL, ECT2, MTDH, PRC1 and RFC4 have all been pre-
viously implicated in breast cancer; SCUBE2 and STK32B
deletions have been found to be related to mental deficits
in humans; and ZNF533 has been found to be associated
with the Hedgehog signaling pathway in Zebrafish [26-
35]. Of note, MTDH activation by 8q22 genomic gain
promotes chemoresistance and metastasis of poor-prog-
nosis breast cancer [36]. The eight genes themselves
could play an important role in the prognosis of breast
cancer. Alternatively, their expression levels could vary in
response to changes in the expression of more influential
genes. This means that rather than identifying the ulti-
mate genetic cause of a cancer, gene expression profiles
may instead provide information about the molecular
consequences of critical mutations. In our population,
the 8-gene Score identified groups of patients whose
DMFS rates differed, both in the whole patient popula-
tion and in the node positive and node negative sub-
groups (figure 1). A sub-analysis of patients receiving
endocrine therapy and no chemotherapy showed the pos-
sible relevance of the 8-gene profile for decision of che-
motherapy.
According to the results from the NKI series [16], the 8-
gene Score performed as well as the 70-Gene Signature
(Additional file 5 table S4). The DMFS and OS rate values
were higher using the 70-Gene Signature, probably due to
the different number of patients assigned to low- versus
high-risk groups in each profile, as well as to the fact that
many women in the NKI series did not receive adjuvant
therapy [37].
The 8-gene Score did not perform as well in other data
sets as it did in ours, probably because of substantial dif-
ferences in the use of adjuvant therapy. For instance,
many women with estrogen receptor-positive tumors did
not receive adjuvant hormonal therapy in the UPP series,
Figure 2 Distant metastasis-free survival (DMFS) rates as a con-
tinuous function of the 8-gene Score. The red line indicates the cut-
off point. Dashed lines indicate the 95% confidence interval.Sánchez-Navarro et al. BMC Cancer 2010, 10:336
http://www.biomedcentral.com/1471-2407/10/336
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Table 3: Multivariate analysis of factors associated with distant metastasis-free survival in the 8-gene Score, the 70-Gene 
Signature and the Recurrence Score
8-Gene Score
HR CI 95% p value
Tumor size 1.31 0.52 - 3.3 0.55
Nodal status 2,87 1.38 - 6.01 0.005
Grade
(2 vs.1)
(3 vs. 1)
0.60
1.42
0.11 - 3.16
0.28 - 7.15
0.227
0.555
0.665
8-gene Score 15.61 4.41 - 55.17 <0.001
70-Gene Signature
HR CI 95% p value
Tumor size 1.4 0.57 - 3.42 0.46
Nodal status 2.70 1.30 - 5.62 0.008
Grade
(2 vs.1)
(3 vs. 1)
0.82
2.349
0.160 - 4.181
0.473 - 11.672
0.113
0.810
0.297
70-Gene Signature 3.505 1.33 - 9.23 0.011
Recurrence Score
HR CI 95% p value
Tumor size * 1.17 0.48 - 2.82 0.72
Nodal status ** 2.49 1.20 - 5.16 0.014
Grade
(2 vs1)
(3 vs 1)
0.68
2.26
0.13 - 3.45
0.49 - 10.40
0.043
0.644
0.292
Recurrence Score
(Interm. vs. Low risk)
(High vs. Low risk)
4.46
8.18
0.78 - 25.33
1.76 - 37.86
0.021
0.091
0.007
*Tumor size: >2 cm vs. ≤2 cm. **Nodal status: positive (1-3) vs negative.Sánchez-Navarro et al. BMC Cancer 2010, 10:336
http://www.biomedcentral.com/1471-2407/10/336
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Figure 3 Kaplan-Meier curves showing distant metastasis-free survival (DMFS) for patients included in four databases available online.
and most did not even receive chemotherapy although
over one third of these patients had positive lymph
nodes[21]. The series by Loi et al. included women with
hormone receptor-positive tumors who were treated with
tamoxifen, but chemotherapy was not used in any patient
[22]. Our profile was generated in a population of women
who had a very good prognosis and received optimal
adjuvant therapy, and therefore the cutoff values identi-
fied using this cohort may be a bit too optimistic for "sub-
optimally" treated populations. This suggests that the 8-
gene Score may provide not only prognostic but also pre-
dictive information. However, because our profile works
as a continuous variable, the cutoff value can be changed
to become less restrictive depending on the patient group
to which it is applied.
Our study has some limitations. Whereas the 70-Gene
Signature and the Recurrence Score have undergone
extensive investigation and clinical use, the 8-gene Score
is still undergoing initial development. Our retrospective
series included a limited number of patients and the
treatment they received was not uniform. Furthermore,
without an independent validation series, we cannot rule
out overestimation of the prognostic value of the 8-gene
Score. The application of our score to external data sets
may temper this limitation, but it is not a formal valida-
tion. Without such validation, the score cannot facilitate
treatment choices, as it neither distinguishes between
therapy benefit nor identifies a group of patients that do
not need any therapy. The use of different populations in
the discovery phase may certainly yield different profiles,
but our point was to demonstrate that a small subset ofSánchez-Navarro et al. BMC Cancer 2010, 10:336
http://www.biomedcentral.com/1471-2407/10/336
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informative genes could provide a significantly prognos-
tic score.
The 8-gene Score correlated very well with two cur-
rently available gene profiles: the 70-Gene Signature and
the Recurrence Score. The discrimination capacity (Har-
rell's C index) was high for all three profiles. The Two-
Gene Index did not perform similarly to the 8-Gene
Score in our cohort of patients, but this does not demon-
strate inferiority. On the other hand, the performance of
this index has recently been improved with the incorpo-
ration of five additional genes related to the tumor grade
[38].
We feel that the 8-gene Score has three main advan-
tages. First, it can be used in FFPE samples with commer-
cial probes. Second, considering the modular nature of
this platform, it would be easy and inexpensive to add
further genes that might provide additional information,
as has been done with the Two-Gene Index [38]. Next
generation profiles could include both prognostic and
predictive information, for instance. Finally, qRT-PCR
using TLDAs can be easily implemented in the clinical
setting.
Conclusions
We have described an 8-gene prognostic Score that can
be used in FFPE samples from patients with early hor-
mone receptor-positive breast cancer. The main interest
of this study is that it opens the door to the use of gene
expression profiling based on small sets of genes in local
laboratories.
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